Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) – Stock analysts at Wedbush issued their Q3 2017 earnings estimates for shares of Allena Pharmaceuticals in a research note issued on Monday. Wedbush analyst L. Moussatos anticipates that the company will earn ($0.46) per share for the quarter. Wedbush has a “Outperform” rating and a $30.00 price target on the stock. Wedbush also issued estimates for Allena Pharmaceuticals’ Q4 2017 earnings at ($0.31) EPS, Q1 2018 earnings at ($0.36) EPS, Q2 2018 earnings at ($0.35) EPS, Q3 2018 earnings at ($0.35) EPS, Q4 2018 earnings at ($0.35) EPS, FY2018 earnings at ($1.42) EPS, FY2019 earnings at ($1.81) EPS, FY2020 earnings at ($2.01) EPS and FY2021 earnings at ($2.49) EPS.

Several other analysts also recently weighed in on ALNA. Jefferies Group began coverage on shares of Allena Pharmaceuticals in a report on Monday, November 27th. They issued a “buy” rating and a $22.00 target price on the stock. Cowen began coverage on shares of Allena Pharmaceuticals in a report on Monday, November 27th. They issued an “outperform” rating on the stock. Finally, Credit Suisse Group began coverage on shares of Allena Pharmaceuticals in a report on Monday, November 27th. They issued an “outperform” rating and a $22.00 target price on the stock.

Allena Pharmaceuticals (NASDAQ ALNA) opened at $14.00 on Thursday. Allena Pharmaceuticals has a one year low of $8.66 and a one year high of $15.00.

In other news, major shareholder Bessemer Venture Partners Vii bought 36,000 shares of the stock in a transaction dated Monday, November 6th. The shares were acquired at an average price of $14.00 per share, with a total value of $504,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James N. Topper bought 500,000 shares of the stock in a transaction dated Monday, November 6th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $7,000,000.00. The disclosure for this purchase can be found here.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/12/01/allena-pharmaceuticals-inc-alna-forecasted-to-earn-q3-2017-earnings-of-0-46-per-share.html.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.

Earnings History and Estimates for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.